Consistent with these findings, a recent multicenter phase III clinical trial demonstrated that nintedanib combined with carboplatin plus albumin-bound paclitaxel effectively preserves lung function and may improve survival outcomes in NSCLC patients with IPF, particularly those with lower GAP scores (42). This evidence concerns the gene ALB and non-small cell lung carcinoma.